BSE filing, NSE: KIMS. Summary written from the filing by ALFA Finder's alert engine.
Krishna Institute of Medical Sciences Ltd: key numbers
- Share price
- ₹705.00
- Market cap
- ₹29,610 Cr
- Revenue (annual)
- ₹3,905 Cr
- Net profit (annual)
- ₹241.4 Cr
- P/E (TTM)
- 144.9×Sector 51.1×
- Promoter holding
- 32.66%+0.16% QoQ
- FII holding
- 15.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krishna Institute of Medical Sciences Ltd
All →Krishna Institute of Medical Sciences Legal & Regulatory
KIMS discloses a pending suit over its Chennai hospital land lease, naming it defendant. Supreme Court dismissed its SLP; no injunction halts the project.
Krishna Institute of Medical Sciences Board Meeting Date
KIMS Ltd informed exchanges of a Board Meeting on November 4, 2026 to approve Q2 and H1 unaudited results. Trading window closes until 48 hours post-disclosure.
Krishna Institute of Medical Sciences Other Announcement
The company filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
Krishna Institute of Medical Sciences Acquisition Worth ₹75 Cr
KIMS will acquire a 51% stake in Insignia Healthcare Private Limited for ₹75 Crore as a strategic investment. This will occur in tranches over 24 months.
- Value
- ₹75.00 Cr
- Execution
- 12 to 24 Months
Krishna Institute of Medical Sciences Acquisition Worth ₹40 Cr
KIMS will acquire a 22% equity stake in Splendid Hospitals Private Limited for up to ₹40 Crore. This strategic investment will be executed via primary infusion.
- Value
- ₹40.00 Cr
- Execution
- On or before 31.03.2027
Krishna Institute of Medical Sciences Acquisition Worth ₹80 Cr
KIMS will acquire a 51% stake in Sarvottam Health Care Private Limited for up to ₹80.00 Crore.
- Value
- ₹80.00 Cr
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.